Research Studies

Aim 1: To enroll 120 non-demented adults with DS (ages 35-55) across 15 sites into the TRC-DS. Aim 2: To determine longitudinal cognitive, clinical and biomarker trajectories in the TRC-DS.

TRC-DS is part of a larger movement working with people with Down syndrome to advance Alzheimer's disease therapies and potential cures for this population. The Alzheimer's Clinical Trials Consortium-Down Syndrome (ACTC-DS) is a large collaboration of researchers conducting clinical trials for Alzheimer's disease in people with Down syndrome. The University of Colorado has partnered with the ACTC-DS to participate on the Anschutz Medical Campus. TRC-DS is the first of these studies and has the goal of creating a group of eligible volunteers with Down syndrome who are interested in participating in future clinical trials.